The evidence for using puberty blocking drugs to treat young people struggling with their gender identity is “very low”, an official review has found.The National Institute of Health and Care Excellence (NICE) said existing studies of the drugs were small and “subject to bias and confounding”.
The assessment of the evidence into the drugs was commissioned by NHS England.
NICE also reviewed the evidence base for gender-affirming hormones – sometimes known as cross-sex hormones.
The review found the evidence of clinical effectiveness and safety of gender-affirming hormones was also of “very low” quality.
“Any potential benefits of gender-affirming hormones must be weighed against the largely unknown long-term safety profile of these treatments in children and adolescents with gender dysphoria,” NICE said.